| Turning liabilities into opportunities: Off-target based drug repurposing in cancer V Palve, Y Liao, LLR Rix, U Rix Seminars in cancer biology 68, 209-229, 2021 | 62 | 2021 |
| Overexpression of Mcl-1L splice variant is associated with poor prognosis and chemoresistance in oral cancers V Palve, S Mallick, G Ghaisas, S Kannan, T Teni PloS one 9 (11), e111927, 2014 | 53 | 2014 |
| A minimal DNA methylation signature in oral tongue squamous cell carcinoma links altered methylation with tumor attributes NM Krishnan, K Dhas, J Nair, V Palve, J Bagwan, G Siddappa, A Suresh, ... Molecular Cancer Research 14 (9), 805-819, 2016 | 51 | 2016 |
| Human oral cancers have altered expression of Bcl‐2 family members and increased expression of the anti‐apoptotic splice variant of Mcl‐1 S Mallick, R Patil, R Gyanchandani, S Pawar, V Palve, S Kannan, ... The Journal of Pathology: A Journal of the Pathological Society of Great …, 2009 | 36 | 2009 |
| Detection of high-risk human papillomavirus in oral cavity squamous cell carcinoma using multiple analytes and their role in patient survival V Palve, J Bagwan, NM Krishnan, M Pareek, U Chandola, A Suresh, ... Journal of global oncology 4, 1-33, 2018 | 31 | 2018 |
| Gene and miRNA expression changes in squamous cell carcinoma of larynx and hypopharynx J Nair, P Jain, U Chandola, V Palve, NRH Vardhan, RB Reddy, ... Genes & cancer 6 (7-8), 328, 2015 | 31 | 2015 |
| Association of anti-apoptotic Mcl-1L isoform expression with radioresistance of oral squamous carcinoma cells VC Palve, TR Teni Radiation Oncology 7, 1-11, 2012 | 30 | 2012 |
| High expression of survivin and its splice variants survivin ΔEx3 and survivin 2 B in oral cancers R Mishra, V Palve, S Kannan, S Pawar, T Teni Oral surgery, oral medicine, oral pathology and oral radiology 120 (4), 497-507, 2015 | 25 | 2015 |
| The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors V Palve, CE Knezevic, DS Bejan, Y Luo, X Li, S Novakova, EA Welsh, ... Cell chemical biology 29 (2), 202-214. e7, 2022 | 24 | 2022 |
| Integrated analysis of oral tongue squamous cell carcinoma identifies key variants and pathways linked to risk habits, HPV, clinical parameters and tumor recurrence N Krishnan, S Gupta, V Palve, L Varghese, S Pattnaik, P Jain, C Khyriem, ... F1000Research 4, 2015 | 23 | 2015 |
| Functional proteomics and deep network interrogation reveal a complex mechanism of action of midostaurin in lung cancer cells C Ctortecka, V Palve, BM Kuenzi, B Fang, NJ Sumi, V Izumi, S Novakova, ... Molecular & Cellular Proteomics 17 (12), 2434-2447, 2018 | 22 | 2018 |
| Targeted therapy given after anti–PD-1 leads to prolonged responses in mouse melanoma models through sustained antitumor immunity MS Phadke, Z Chen, J Li, E Mohamed, MA Davies, I Smalley, DR Duckett, ... Cancer immunology research 9 (5), 554-567, 2021 | 19 | 2021 |
| A minimal set of internal control genes for gene expression studies in head and neck squamous cell carcinoma V Palve, M Pareek, NM Krishnan, G Siddappa, A Suresh, MA Kuriakose, ... PeerJ 6, e5207, 2018 | 9 | 2018 |
| Unraveling the rewired network V Palve, BM Kuenzi, U Rix Nature Chemical Biology 14 (8), 746-747, 2018 | 5 | 2018 |
| Functional genomics screen with pooled shRNA library and gene expression profiling with extracts of Azadirachta indica identify potential pathways for therapeutic targets in … NM Krishnan, H Katoh, V Palve, M Pareek, R Sato, S Ishikawa, B Panda PeerJ 7, e6464, 2019 | 4 | 2019 |
| High-risk human papillomavirus in oral cavity squamous cell carcinoma V Palve, J Bagwan, NM Krishnan, M Pareek, U Chandola, A Suresh, ... | 2 | 2016 |
| Abstract B021: PARP16 is a novel target of talazoparib which contributes to synergy with adavosertib in SCLC V Palve, C Knezevic, Y Luo, X Li, S Novakova, E Welsh, B Fang, F Kinose, ... Molecular Cancer Therapeutics 18 (12_Supplement), B021-B021, 2019 | 1 | 2019 |
| Integrated analysis links TP53, NOTCH, SLC38A and 11p with survival in patients with oral tongue squamous cell carcinoma NM Krishnan, S Gupta, C Khyriem, V Palve, A Suresh, G Siddappa, ... bioRxiv, 033829, 2015 | 1 | 2015 |
| Combination of a chk1/2 dual inhibitor (prexasertib) and gemcitabine reveals a novel intrinsic synergy mechanism in head and neck squamous cell carcinoma VC Palve, HL Walker-Mimms, R Chaudhary, V Izumi, N Chaudhary, ... Cancer Research 84 (6_Supplement), 3368-3368, 2024 | | 2024 |
| Abstract C054: PARP16 modulates MYC expression and susceptibility of Ewing’s Sarcoma cells to PARP1 inhibition O Deng, X Li, VC Palve, B Fang, DR Reed, U Rix Molecular Cancer Therapeutics 22 (12_Supplement), C054-C054, 2023 | | 2023 |
